Axe Compute Inc. Joins Russell Microcap® Index, Reflecting Its Growth as a Publicly Traded AI Infrastructure Platform
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026
Patrick Gruber, CEO of Gevo (NASDAQ: GEVO), shares how the company is pioneering renewable, drop-in hydrocarbon jet fuels that are cost-competitive with traditional petroleum-based alternatives. With over 450 patents and projects backed by a $1.63B DOE loan guarantee, Gevo is scaling commercial production through facilities in South Dakota and North Dakota. The company’s ethanol-based jet fuel, carbon capture, and RNG assets are unlocking significant revenue streams—positioning Gevo to become EBITDA positive in 2025. With $270M+ in cash, strategic partnerships, and bipartisan support for 45Z tax credits, Gevo is accelerating the transition to net-zero aviation fuels.
May 22, 2025
June 29, 2026
Purchase order supports ParaZero’s continued expansion and reinforces customer confidence in the Company’s technology platform and engineering capabilities Kfar Saba, Israel, July 06, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero” or the “Company”), an aerospace defense technology company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems industry, today announced […]
July 6, 2026
A prominent Charlotte entrepreneur — and the former business partner of disgraced financier Rick Siskey — has been sued by the federal government, accused of making numerous unauthorized trades that hurt his investors but benefited himself. In its filing, the Atlanta office of the U.S. Securities and Exchange Commission claims that Martin Sumichrast, 55, repeatedly made investments that damaged the positions of […]
June 3, 2022
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data […]
April 30, 2026
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026
July 7, 2026